<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02764671</url>
  </required_header>
  <id_info>
    <org_study_id>KT0012</org_study_id>
    <nct_id>NCT02764671</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of Recombinant Hepatitis B Vaccines in the Neonates</brief_title>
  <official_title>The Safety and Immunogenicity of 10μg/0.5ml Recombinant Hepatitis B Vaccines(Saccharomyces Cerevisiae) in the Healthy Neonates</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenzhen Kangtai Biological Products Co., LTD</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Guangdong Provincial Institute of Biological Products And Materia Medica</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shenzhen Kangtai Biological Products Co., LTD</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to further evaluate the immunogenicity and safety of 10μg/0.5ml
      Recombinant Hepatitis B Vaccines(Saccharomyces Cerevisiae) in the Healthy Neonates.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with adverse events</measure>
    <time_frame>Within 30 days after hepatitis B vaccination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric mean titer of anti-hepatitis B virus surface antigen antibody</measure>
    <time_frame>The 30th day after whole course of hepatitis B vaccination</time_frame>
    <description>Geometric mean titer of anti-hepatitis B virus surface antigen antibody was measured by chemiluminescence assay and expressed with mIU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean titer of anti-hepatitis B virus surface antigen antibody</measure>
    <time_frame>The 1th year after whole course of hepatitis B vaccination</time_frame>
    <description>Geometric mean titer of anti-hepatitis B virus surface antigen antibody was measured by chemiluminescence assay and expressed with mIU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean titer of anti-hepatitis B virus surface antigen antibody</measure>
    <time_frame>The 2th year after whole course of hepatitis B vaccination</time_frame>
    <description>Geometric mean titer of anti-hepatitis B virus surface antigen antibody was measured by chemiluminescence assay and expressed with mIU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean titer of anti-hepatitis B virus surface antigen antibody</measure>
    <time_frame>The 3th year after whole course of hepatitis B vaccination</time_frame>
    <description>Geometric mean titer of anti-hepatitis B virus surface antigen antibody was measured by chemiluminescence assay and expressed with mIU/mL.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Hepatitis</condition>
  <condition>Hepatitis B</condition>
  <condition>Liver Diseases</condition>
  <condition>Digestive System Diseases</condition>
  <arm_group>
    <arm_group_label>10μg/0.5ml recombinant HBV vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5000 participants who are healthy neonates receive 10μg/0.5ml recombinant hepatitis B vaccine on day 0, 30 and 60.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>10μg/0.5ml recombinant hepatitis B vaccine</intervention_name>
    <description>5000 participants who are healthy neonates receive 10μg/0.5ml recombinant hepatitis B vaccine on day 0, 30 and 60.</description>
    <arm_group_label>10μg/0.5ml recombinant HBV vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who are healthy full-term infants after birth, Apgar score ≥8;

          -  Subjects with a birth weight ≥ 2500g;

          -  Subjects' guardians are able to understand and sign informed consent;

          -  Subjects who can and will comply with the requirements of the protocol.

        Exclusion Criteria:

          -  Family history of eclampsia, epilepsy and encephalopathy;

          -  Subjects' birth mother had immune system dysfunction, or history of organ
             transplantation or blood dialysis;

          -  Subjects' parents had a medical history of allergic to any ingredient of the vaccine,
             including supplementary material and formaldehyde;

          -  Subjects' parents had a medical history of allergic to combined hepatitis A and B
             vaccine(HAB) or hepatitis B vaccine;

          -  Subjects had serious acute and chronic diseases;

          -  with temperature ≧37.1℃;

          -  Any condition that in the opinion of the investigator, may interfere with the
             evaluation of study objectives.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>24 Hours</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zheng Huizhen, master</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangdong Center for Disease Prevention and Control</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Huang Zhuhang, master</last_name>
    <phone>+86-020-36271871</phone>
    <email>jade_lyy@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Gaozhou District Center for Disease Control and Prevention</name>
      <address>
        <city>Maoming</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huang Zhuhang, Master</last_name>
      <phone>+86-020-36271871</phone>
      <email>jade_lyy@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xinxing District Center for Disease Control and Prevention</name>
      <address>
        <city>Yunfu</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huang Zhuhang, master</last_name>
      <phone>+86-020-36271871</phone>
      <email>jade_lyy@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2016</study_first_submitted>
  <study_first_submitted_qc>May 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2016</study_first_posted>
  <last_update_submitted>May 5, 2016</last_update_submitted>
  <last_update_submitted_qc>May 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recombinant hepatitis B vaccine</keyword>
  <keyword>safety</keyword>
  <keyword>immunogenicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Digestive System Diseases</mesh_term>
    <mesh_term>Gastrointestinal Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

